-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The addition of the immunotherapy drug nivolumab to preoperative (neoadjuvant) chemotherapy in patients with operable non-small cell lung cancer (NSCLC) reduces the risk of cancer recurrence or death by more than three-fold, results from the CheckMate-816 phase III trial show one
The study, led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, led to Federal Drug Administration (FDA) approval of the first drug for operable non-small cell Immunotherapy/chemotherapy combination therapy in patients with cell lung cancer
The findings were published online April 11 in the New England Journal of Medicine
"In this trial, we found that adding nivolumab to standard neoadjuvant chemotherapy reduced the risk of cancer recurrence or death by more than a third
The standard treatment for resectable lung cancer is surgical removal of the tumor, Ford said
"We show for the first time that for newly diagnosed patients with stage 1-3 NSCLC, giving immunotherapy before surgery does improve outcomes
In this study, 358 patients with stage 1B-3A resectable NSCLC were randomly assigned to receive 3 cycles of standard platinum doublet chemotherapy with or without 360 mg of the anti-PD-1 immunotherapy drug nivolumab, followed by surgery
Pathological complete response was defined as the absence of remaining viable tumor on postoperative examination of lung tumors and lymph nodes
The current findings build on a small 2018 study by Ford, Drew Pardoll, MD, director of the Bloomberg-Kimmore Cancer Immunotherapy Institute, and Julie Brah.
"We are excited to add new treatment options to this group of patients, who have historically been difficult to treat," said study co-author Stephen Broderick, MD, MPH, John Hope Associate Director of the Cardiothoracic Surgery Residency Program at Kings University and a thoracic surgeon treating lung cancer patients at the Johns Hopkins Kimmel Cancer Center
